vs
渤健（BIIB）与RXO, Inc.（RXO）财务数据对比。点击上方公司名可切换其他公司
渤健的季度营收约是RXO, Inc.的1.7倍（$2.5B vs $1.5B），渤健净利率更高（12.9% vs -3.1%，领先16.0%），渤健同比增速更快（2.0% vs -11.9%），渤健自由现金流更多（$594.3M vs $-9.0M），过去两年RXO, Inc.的营收复合增速更高（26.8% vs 0.3%）
渤健是总部位于美国马萨诸塞州剑桥市的跨国生物技术企业，专注于神经系统疾病治疗领域。公司核心产品包括用于多发性硬化症的特菲达、万立能等多款药物，以及治疗脊髓性肌萎缩症的诺西那生钠、治疗弗里德赖希共济失调的Skyclarys，致力于为神经疾病和罕见病患者提供创新疗法。
RXO是总部位于美国的头部运输及物流解决方案供应商，核心业务覆盖货运经纪、大件商品最后一公里配送、运输管理服务与全链路供应链优化支持，主要服务北美制造业、零售业及电商领域的客户。
BIIB vs RXO — 直观对比
营收规模更大
BIIB
是对方的1.7倍
$1.5B
营收增速更快
BIIB
高出13.9%
-11.9%
净利率更高
BIIB
高出16.0%
-3.1%
自由现金流更多
BIIB
多$603.3M
$-9.0M
两年增速更快
RXO
近两年复合增速
0.3%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $2.5B | $1.5B |
| 净利润 | $319.5M | $-46.0M |
| 毛利率 | — | — |
| 营业利润率 | — | -2.9% |
| 净利率 | 12.9% | -3.1% |
| 营收同比 | 2.0% | -11.9% |
| 净利润同比 | 32.8% | -84.0% |
| 每股收益（稀释后） | $2.15 | $-0.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BIIBRXO
| Q1 26 | $2.5B | — | ||
| Q4 25 | $2.3B | $1.5B | ||
| Q3 25 | $2.5B | $1.4B | ||
| Q2 25 | $2.6B | $1.4B | ||
| Q1 25 | $2.4B | $1.4B | ||
| Q4 24 | $2.5B | $1.7B | ||
| Q3 24 | $2.5B | $1.0B | ||
| Q2 24 | $2.5B | $930.0M |
净利润BIIBRXO
| Q1 26 | $319.5M | — | ||
| Q4 25 | $-48.9M | $-46.0M | ||
| Q3 25 | $466.5M | $-14.0M | ||
| Q2 25 | $634.8M | $-9.0M | ||
| Q1 25 | $240.5M | $-31.0M | ||
| Q4 24 | $266.7M | $-25.0M | ||
| Q3 24 | $388.5M | $-243.0M | ||
| Q2 24 | $583.6M | $-7.0M |
毛利率BIIBRXO
| Q1 26 | — | — | ||
| Q4 25 | 78.3% | — | ||
| Q3 25 | 73.4% | — | ||
| Q2 25 | 77.1% | — | ||
| Q1 25 | 74.1% | — | ||
| Q4 24 | 76.2% | — | ||
| Q3 24 | 74.1% | — | ||
| Q2 24 | 77.8% | — |
营业利润率BIIBRXO
| Q1 26 | — | — | ||
| Q4 25 | -2.5% | -2.9% | ||
| Q3 25 | 22.0% | -0.5% | ||
| Q2 25 | 28.1% | — | ||
| Q1 25 | 12.8% | -2.1% | ||
| Q4 24 | 11.9% | -1.4% | ||
| Q3 24 | 18.3% | -1.9% | ||
| Q2 24 | 28.3% | — |
净利率BIIBRXO
| Q1 26 | 12.9% | — | ||
| Q4 25 | -2.1% | -3.1% | ||
| Q3 25 | 18.4% | -1.0% | ||
| Q2 25 | 24.0% | -0.6% | ||
| Q1 25 | 9.9% | -2.2% | ||
| Q4 24 | 10.9% | -1.5% | ||
| Q3 24 | 15.8% | -23.4% | ||
| Q2 24 | 23.7% | -0.8% |
每股收益（稀释后）BIIBRXO
| Q1 26 | $2.15 | — | ||
| Q4 25 | $-0.35 | $-0.28 | ||
| Q3 25 | $3.17 | $-0.08 | ||
| Q2 25 | $4.33 | $-0.05 | ||
| Q1 25 | $1.64 | $-0.18 | ||
| Q4 24 | $1.82 | $-0.17 | ||
| Q3 24 | $2.66 | $-1.81 | ||
| Q2 24 | $4.00 | $-0.06 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $3.4B | $17.0M |
| 总债务越低越好 | — | $387.0M |
| 股东权益账面价值 | $18.7B | $1.5B |
| 总资产 | $29.5B | $3.3B |
| 负债/权益比越低杠杆越低 | — | 0.25× |
8季度趋势，按日历期对齐
现金及短期投资BIIBRXO
| Q1 26 | $3.4B | — | ||
| Q4 25 | — | $17.0M | ||
| Q3 25 | — | $25.0M | ||
| Q2 25 | — | $18.0M | ||
| Q1 25 | — | $16.0M | ||
| Q4 24 | — | $35.0M | ||
| Q3 24 | — | $55.0M | ||
| Q2 24 | — | $7.0M |
总债务BIIBRXO
| Q1 26 | — | — | ||
| Q4 25 | $6.3B | $387.0M | ||
| Q3 25 | $6.3B | $387.0M | ||
| Q2 25 | $6.3B | $387.0M | ||
| Q1 25 | $4.5B | $387.0M | ||
| Q4 24 | $6.3B | $351.0M | ||
| Q3 24 | $4.5B | $352.0M | ||
| Q2 24 | $6.3B | $370.0M |
股东权益BIIBRXO
| Q1 26 | $18.7B | — | ||
| Q4 25 | $18.3B | $1.5B | ||
| Q3 25 | $18.2B | $1.6B | ||
| Q2 25 | $17.6B | $1.6B | ||
| Q1 25 | $17.0B | $1.6B | ||
| Q4 24 | $16.7B | $1.6B | ||
| Q3 24 | $16.4B | $1.7B | ||
| Q2 24 | $15.9B | $579.0M |
总资产BIIBRXO
| Q1 26 | $29.5B | — | ||
| Q4 25 | $29.4B | $3.3B | ||
| Q3 25 | $29.2B | $3.2B | ||
| Q2 25 | $28.3B | $3.2B | ||
| Q1 25 | $28.0B | $3.3B | ||
| Q4 24 | $28.0B | $3.4B | ||
| Q3 24 | $28.3B | $3.4B | ||
| Q2 24 | $26.8B | $1.8B |
负债/权益比BIIBRXO
| Q1 26 | — | — | ||
| Q4 25 | 0.34× | 0.25× | ||
| Q3 25 | 0.35× | 0.24× | ||
| Q2 25 | 0.36× | 0.24× | ||
| Q1 25 | 0.27× | 0.24× | ||
| Q4 24 | 0.38× | 0.22× | ||
| Q3 24 | 0.28× | 0.21× | ||
| Q2 24 | 0.40× | 0.64× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $7.0M |
| 自由现金流经营现金流 - 资本支出 | $594.3M | $-9.0M |
| 自由现金流率自由现金流/营收 | 24.0% | -0.6% |
| 资本支出强度资本支出/营收 | — | 1.1% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $2.4B | $-8.0M |
8季度趋势，按日历期对齐
经营现金流BIIBRXO
| Q1 26 | — | — | ||
| Q4 25 | $511.9M | $7.0M | ||
| Q3 25 | $1.3B | $23.0M | ||
| Q2 25 | $160.9M | $23.0M | ||
| Q1 25 | $259.3M | $-2.0M | ||
| Q4 24 | $760.9M | $-7.0M | ||
| Q3 24 | $935.6M | $-7.0M | ||
| Q2 24 | $625.8M | $-5.0M |
自由现金流BIIBRXO
| Q1 26 | $594.3M | — | ||
| Q4 25 | $468.0M | $-9.0M | ||
| Q3 25 | $1.2B | $9.0M | ||
| Q2 25 | $134.3M | $9.0M | ||
| Q1 25 | $222.2M | $-17.0M | ||
| Q4 24 | $721.6M | $-19.0M | ||
| Q3 24 | $900.6M | $-18.0M | ||
| Q2 24 | $592.3M | $-16.0M |
自由现金流率BIIBRXO
| Q1 26 | 24.0% | — | ||
| Q4 25 | 20.5% | -0.6% | ||
| Q3 25 | 48.4% | 0.6% | ||
| Q2 25 | 5.1% | 0.6% | ||
| Q1 25 | 9.1% | -1.2% | ||
| Q4 24 | 29.4% | -1.1% | ||
| Q3 24 | 36.5% | -1.7% | ||
| Q2 24 | 24.0% | -1.7% |
资本支出强度BIIBRXO
| Q1 26 | — | — | ||
| Q4 25 | 1.9% | 1.1% | ||
| Q3 25 | 1.8% | 1.0% | ||
| Q2 25 | 1.0% | 1.0% | ||
| Q1 25 | 1.5% | 1.0% | ||
| Q4 24 | 1.6% | 0.7% | ||
| Q3 24 | 1.4% | 1.1% | ||
| Q2 24 | 1.4% | 1.2% |
现金转化率BIIBRXO
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 2.73× | — | ||
| Q2 25 | 0.25× | — | ||
| Q1 25 | 1.08× | — | ||
| Q4 24 | 2.85× | — | ||
| Q3 24 | 2.41× | — | ||
| Q2 24 | 1.07× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BIIB
| Product revenue, net | $1.8B | 71% |
| Royalty revenue on sales of OCREVUS | $317.2M | 13% |
| Contract manufacturing, royalty and other revenue | $246.9M | 10% |
| Biogen's share of pre-tax profits in the U.S. for RITUXAN, GAZYVA and LUNSUMIO | $94.7M | 4% |
| Alzheimer's collaboration Revenue | $59.5M | 2% |
| Other revenue from anti-CD20 therapeutic programs | $7.2M | 0% |
RXO
| Retail Sector | $546.0M | 37% |
| Last Mile | $298.0M | 20% |
| Food And Beverage Sector | $225.0M | 15% |
| Other Sector | $185.0M | 13% |
| Managed Transportation | $133.0M | 9% |
| Automotive Sector | $93.0M | 6% |
